Sign inJoin waitlistJoin the waitlist

Sam Milanovich

Pediatric Student Research Advisor · Univ of North Dakota School of Medicine and Health Sciences

Credentials: · · · · · · · ·

History

Sanford Health of Northern Minnesota
2026–Present

Pediatric Hematology-Oncology
2009–2010
Pediatrics
UPMC Medical Education
2006–2009
University of North Dakota School of Medicine and Health Sciences
2002–2006

Research

Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes
Blood · 2013 · 116 citations
Concise Review: Fat and Furious: Harnessing the Full Potential of Adipose-Derived Stromal Vascular Fraction
Review · Stem Cells Translational Medicine · 2017 · 82 citations
The cohesin subunit Rad21 is a negative regulator of hematopoietic self-renewal through epigenetic repression of Hoxa7 and Hoxa9
Leukemia · 2017 · 60 citations

Sridhar Rao
5 papers
Jeremy Allred
2 papers · 1 as a resident
SB
Steven Blinka
2 papers
AF
Alexandra Filipovich
1 paper
Ashish Kumar
1 paper
Ashley Hill
1 paper
AF
Asmaa Ferdjallah
1 paper · 1 as a fellow
CS
Christopher Strouse
1 paper · 1 as a fellow
David Dickens
1 paper
David Dimmock
1 paper
David Margolis
1 paper
DL
Dorothea Lindsay
1 paper

Grants

Sanford Community Cancer Program of the North Central Plains (NCORP)
National Cancer Institute · UG1
Contact PI · $4.9M · Sanford Research/Usd
2014–2027
Effect of Novel Extracellular Superoxide Dismutase Mimetics in the Scopolamine Cognitive Impairment Model for Alzheimer's Disease
National Institute of General Medical Sciences · P20
Project lead · $1.2M · Sanford Research/Usd

Clinical trials

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
Site PI · Recruiting · Phase 3
Children's Oncology Group
2026–2033
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2029